191 related articles for article (PubMed ID: 36573731)
1. Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.
Zondra Revendova K; Starvaggi Cucuzza C; Manouchehrinia A; Khademi M; Bar M; Leppert D; Sandberg E; Ouellette R; Granberg T; Piehl F
Brain Behav; 2023 Jan; 13(1):e2873. PubMed ID: 36573731
[TBL] [Abstract][Full Text] [Related]
2. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Rosenstein I; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Mult Scler; 2022 May; 28(6):872-884. PubMed ID: 34392718
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
5. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.
Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F
Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673
[TBL] [Abstract][Full Text] [Related]
6. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
7. Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.
Rosenstein I; Rasch S; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Front Immunol; 2022; 13():967953. PubMed ID: 36032114
[TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor and neurofilament light chain in cerebrospinal fluid are inversely correlated with cognition in Multiple Sclerosis at the time of diagnosis.
Yalachkov Y; Anschütz V; Jakob J; Schaller-Paule MA; Schäfer JH; Reiländer A; Friedauer L; Behrens M; Steffen F; Bittner S; Foerch C
Mult Scler Relat Disord; 2022 Jul; 63():103822. PubMed ID: 35504173
[TBL] [Abstract][Full Text] [Related]
9. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
10. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
12. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
[TBL] [Abstract][Full Text] [Related]
13. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
[TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
[TBL] [Abstract][Full Text] [Related]
16. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
Ning L; Wang B
PLoS One; 2022; 17(9):e0274565. PubMed ID: 36103562
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.
Abdelhak A; Benkert P; Schaedelin S; Boscardin WJ; Cordano C; Oechtering J; Ananth K; Granziera C; Melie-Garcia L; Montes SC; Beaudry-Richard A; Achtnichts L; Oertel FC; Lalive PH; Leppert D; Müller S; Henry RG; Pot C; Matthias A; Salmen A; Oksenberg JR; Disanto G; Zecca C; D'Souza M; Du Pasquier R; Bridel C; Gobbi C; Kappos L; Hauser SL; Cree BAC; Kuhle J; Green AJ;
JAMA Neurol; 2023 Dec; 80(12):1317-1325. PubMed ID: 37930670
[TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
[TBL] [Abstract][Full Text] [Related]
20. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
